PBAC's latest decision on Methotrexate (as sodium): Recommended (2024). Considered for New formulation of methotrexate (as sodium) 2.5 mg and 10 mg tablets for listing under the same circumstances as the currently PBS-listed methotrexate tablets, including treatment of patients requiring doses greater than 20 mg per week.
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2024
Submissions
1
2024 → 2024
Eligible population
Patients with indications for methotrexate therapy, including those requiring doses greater than 20 mg per week (for the 50-unit pack listing).
Therapy area
Rheumatology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
methotrexate (current formulation)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated as the submission involved bioequivalent formulation with equivalent pricing.